Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Wu X, Luo Y, Liu L, Han C, Liu Y, Zhang Z Inflammation. 2025; .
PMID: 39786459 DOI: 10.1007/s10753-024-02216-x.
References
1.
Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F
. Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clin Cosmet Investig Dermatol. 2023; 16:2045-2059.
PMC: 10408653.
DOI: 10.2147/CCID.S407813.
View
2.
Rosenbach M, Hsu S, Korman N, Lebwohl M, Young M, Bebo Jr B
. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009; 62(4):655-62.
DOI: 10.1016/j.jaad.2009.05.048.
View
3.
Dogra S, Mehta H
. Biological treatment for erythrodermic psoriasis. Expert Opin Biol Ther. 2022; 22(12):1531-1543.
DOI: 10.1080/14712598.2022.2128669.
View
4.
Damiani G, Pacifico A, Russo F, Pigatto P, Bragazzi N, Bonifati C
. Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study. J Clin Med. 2019; 8(6).
PMC: 6617329.
DOI: 10.3390/jcm8060770.
View
5.
Avallone G, Cariti C, Dapavo P, Ortoncelli M, Conforto L, Mastorino L
. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022; 36(7):e574-e576.
DOI: 10.1111/jdv.18069.
View